2025-12-17 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly and Co. (LLY), combining the provided data and analysis.

**Report on Eli Lilly and Co. (LLY)**

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Eli Lilly and Co. is a pharmaceutical company that develops and markets medicines.
*   **LLY Cumulative Return:** 299.13%
*   **VOO Cumulative Return:** 99.81%
*   **Divergence:** 174.4 (Relative Divergence: 73.7)

**Analysis:**

LLY has significantly outperformed the S&P 500. The current divergence suggests that while LLY's outperformance is substantial, its relative position within its historical range of divergence is above average, but not at the extreme high. This could indicate sustained strength but with potential for volatility.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 11.0%  | 76.1% | -17.0% | -0.0 | 75.7   |
| 2016-2018  | 39.0%  | 68.9% | 24.0%  | -0.0 | 103.7  |
| 2017-2019  | 41.0%  | 68.9% | 19.0%  | 0.4  | 117.8  |
| 2018-2020  | 34.0%  | 79.8% | 10.0%  | 0.4  | 151.4  |
| 2019-2021  | 53.0%  | 79.8% | 7.0%   | 0.5  | 247.6  |
| 2020-2022  | 64.0%  | 79.8% | 65.0%  | 0.4  | 328.0  |
| 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2  | 522.6  |
| 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2  | 692.1  |
| 2023-2025  | 190.0% | 83.5% | 126.0% | 0.2  | 945.1  |

**Analysis:**

*   **CAGR:** Demonstrates strong growth in recent years, particularly from 2021-2025.
*   **MDD:**  The Maximum Drawdown is relatively high, indicating significant price volatility.
*   **Alpha:** Recent Alpha figures are very high, indicating significant outperformance relative to its risk.
*   **Beta:** Beta values are low, suggesting that LLY's price movements are not strongly correlated with the broader market. A beta near 0 suggests very little correlation.
*   **Cap(B):** Market Cap has shown tremendous growth.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 1054.29
*   **Previous Close:** 1062.19
*   **Change:** -0.74%
*   **5-day SMA:** 1029.40
*   **20-day SMA:** 1040.20
*   **60-day SMA:** 915.00

**Analysis:**

The current price is below both the 20-day and previous close SMA, suggesting a short-term downtrend. However, the 20-day SMA is above the 60-day SMA, indicating a longer-term uptrend remains intact.

**3. Market Risk Indicator, RSI, PPO, and Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 37.46
*   **PPO:** -0.63
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent Relative Divergence Change (20 days):** -5.8 (Negative - Short-term decline)
*   **Expected Return (%):** 65.8%

**Analysis:**

*   The MRI of 0.7 suggests a medium investment recommendation, implying a moderate level of risk.
*   The RSI of 37.46 is approaching oversold territory (below 30), potentially signaling a buying opportunity.
*   The negative PPO suggests the stock is experiencing a short-term downtrend relative to its longer-term moving averages.
*   The hybrid signal is a strong buy and the company has no debt, meaning that they have financial stability and that may be why the signal has been set to the strongest rating possible.
*   The negative change in relative divergence confirms the short-term decline.
*   The high expected return (65.8%) indicates significant potential for long-term growth, exceeding the S&P 500.

**4. Recent News & Significant Events**

*   **Strong Buy Recommendations:** Multiple articles highlight LLY as a top "Growth Stock" for 2026.
*   **Weight-Loss Drug Dominance:**  Bank of America suggests the market isn't fully pricing in LLY's potential in the weight-loss drug market.
*   **Long-Term Outlook:**  Articles discuss where Eli Lilly will be in 10 years.
*   **Dividend Increase:** LLY is among healthcare giants that recently raised dividends.

**Analysis:**

Recent news is predominantly positive, focusing on LLY's growth potential, particularly in the weight-loss drug market, and strong financial performance reflected in dividend increases.  The strong buy recommendations from analysts further reinforce positive sentiment.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.77)
*   **Opinions:** 27
*   **Target Price:** Avg: 1075.07 / High: 1500.00 / Low: 770.00
*   **Recent Rating Changes:** Not available

**Analysis:**

The analyst consensus is a "Buy" with a mean rating of 1.77. The average target price of $1075.07 suggests a slight upside potential from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.30 | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2025-10-30 | 1.08 | 11.44 B$  |

**Analysis:**

*   **EPS:** Shows a strong upward trend in 2025, particularly in the most recent quarters.
*   **Revenue:** Revenue has also been consistently increasing, indicating robust growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $23.79B   | 23.46%   |
| 2025-06-30   | $18.27B   | 30.98%   |
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |

**Analysis:**

*   **Revenue:** Strong and consistent revenue growth over the past five quarters.
*   **Profit Margin:** Exceptionally high and stable profit margins, indicating efficient operations and strong pricing power.
*   **Equity:** Significant growth in equity, reflecting retained earnings and value creation.
*   **ROE:** Return on Equity is volatile with big swings.

**7. Comprehensive Analysis**

Eli Lilly and Co. (LLY) is exhibiting strong growth characteristics and significantly outperforming the S&P 500. The company's financial performance is impressive, with robust revenue growth, high profit margins, and increasing equity.  Recent earnings data confirms the upward trend. Analyst opinions are overwhelmingly positive, and the company is receiving favorable coverage in the news, particularly regarding its potential in the weight-loss drug market.

**Key Takeaways:**

*   **Strong Growth Stock:** LLY demonstrates characteristics of a strong growth stock, driven by innovation and market opportunities.
*   **Positive Outlook:** The overall outlook is positive, supported by strong financials, analyst ratings, and favorable news.
*   **Short-Term Downtrend:** Recent price action suggests a short-term downtrend, but the long-term trend remains positive.
*   **Potential Risks:** High MDD suggests volatility.
*   **Overall Recommendation:** The data suggests a buy recommendation, particularly for long-term investors. However, be mindful of short-term volatility.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.